3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Prostatic Neoplasms
9
Breast Neoplasms
7
Obesity
4
Colorectal Neoplasms
4
Rectal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sarcoma
2
Radiation Injuries
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Weight Loss
1
Uterine Cervical Dysplasia
1
Stage IV Breast Cancer AJCC v6 and v7
1
Sezary Syndrome
1
Sexuality
1
Sexual Dysfunction, Physiological
1
Prostate Adenocarcinoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Patient Compliance
1
Overweight
1
Neuroendocrine Tumors
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Interventions
Temozolomide
203
Radiotherapy
118
Bevacizumab
93
Radiation
40
Magnetic Resonance Spectroscopy
28
Irinotecan
27
Carmustine
25
Surgical Procedures, Operative
24
Lomustine
21
Erlotinib Hydrochloride
19
Chemotherapy, Adjuvant
18
Carboplatin
17
temsirolimus
13
Drug Therapy
13
O(6)-benzylguanine
12
Nivolumab
12
sargramostim
11
Sirolimus
11
Radiotherapy, Intensity-Modulated
11
Radiotherapy, Conformal
11
Sorafenib
10
Radiosurgery
10
Imatinib Mesylate
10
Everolimus
10
pembrolizumab
9
motexafin gadolinium
9
Vorinostat
9
Thalidomide
8
IL13-PE38
8
Gefitinib
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Glioblastoma
×
Diet Therapy
×
Clear all
NCT02286167
2026-03-24
GLAD
Wake Forest University Health Sciences
Phase NA
Completed
25 enrolled